# mFOLFIRI Combine With Nimotuzumab Second Line Chemotherapy for Squamous-cell Carcinoma of the Esophagus

> **NCT01486992** · PHASE2 · UNKNOWN · sponsor: **Peking University** · enrollment: 40 (estimated)

## Conditions studied

- Advanced Esophageal Carcinoma

## Interventions

- **DRUG:** mFOLFIRI+Nimotuzumab

## Key facts

- **NCT ID:** NCT01486992
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-11
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2012-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01486992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01486992, "mFOLFIRI Combine With Nimotuzumab Second Line Chemotherapy for Squamous-cell Carcinoma of the Esophagus". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT01486992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*